Longhorn Vaccines and Diagnostics Presents New Data on its Best-In-Class Infectious Disease Vaccine and Antibody Portfolio at ECCMID 2024
27 Abril 2024 - 7:00AM
Business Wire
- LHNVD-105, a universal influenza vaccine, shows strong
immunogenicity at low doses in pigs, validating previous studies in
rodents
- Monoclonal antibodies generated by LHNVD-105 demonstrates the
need for targeting multiple different conserved regions on the
influenza virus
- LHNVD-301, a monoclonal antibody cocktail targeting the heat
shock protein, demonstrates strong activity against clinical
tuberculosis isolates
Longhorn Vaccines and Diagnostics, a One Health company
developing vaccines and diagnostic tools for global public health
and zoonosis concerns, presented positive data from three key
studies of its infectious disease franchise at the European
Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
2024. ECCMID is taking place online and in-person in Barcelona,
Spain from April 27-30, 2024.
Longhorn’s vaccine and antibody product candidates focus on
rapidly mutating viruses that include influenza, coronavirus, and
antimicrobial resistant pathogens. The candidates presented include
LHNVD-105, an adjuvanted composite peptide vaccine that targets
multiple stages of the viral replication process, and a monoclonal
antibody cocktail that targets a protein that may play a
significant role in allowing tuberculosis to remain in a latent
stage.
Influenza is a prevalent zoonotic respiratory virus, with pigs
acting as a middleman for generating new virus strains
transferrable to humans, birds, and other swine with pandemic
potential. This poses a major public health issue and challenges to
the swine industry. The first of two studies on LHNVD-105,
Longhorn’s universal influenza vaccine, showcased how unconjugated
multi-epitope peptides, formulated with AddaVaxTM adjuvant,
generated antibodies that were broadly reactive across multiple
influenza virus strains when administered to pigs at low doses.
Results included:
- Pigs immunized with LHNVD-105 generated IgG antibodies that
bound to multiple strains of influenza virus 21 days post primary
immunization after a single dose.
- Pigs receiving low vaccine doses (1 and 5μg) generated binding
antibodies to influenza viruses equal to or higher than pigs in the
high dose groups (50 and 100μg).
- No adverse reactions to the vaccine were observed.
“We are very excited to present the first data from our
universal influenza vaccine in pigs,” said Jeff Fischer, President
Longhorn Vaccines and Diagnostics. “Pigs are an ideal model for
influenza and the results mirrored the significant rodent data that
has been previously published.”
Seasonal circulation of rapidly evolving influenza strains are
potential threats in human populations. For individuals with
increased risk of exposure to influenza or immunocompromised, new
strains resistant to antiviral therapies pose a life-threatening
risk. The second study on LHNVD-105 evaluated the binding and
functional capabilities of four different isotype-specific
anti-influenza mAbs in mice to determine their candidacy for a
cocktail therapy approach to influenza. Results demonstrated:
- Anti-influenza mAbs LD9 (IgG1, anti-HA), NB5 (IgG2a, anti-NA),
GA4 (IgG1, anti-Matrix), and CG6, (IgG3, anti-Matrix) bound equally
well to H3N2, but differentially to other contemporary and pandemic
strains.
- Anti-HA mAb LD9 and anti-Matrix mAb GA4 (both IgG1)
preferentially bound to pandemic H5N1 influenza strain, while
anti-Matrix mAb CG6 was more reactive with influenza B.
- Anti-NA mAb NB5 and anti-Matrix mAb CG6 both had higher
affinities to H3N2 and influenza B, but reacted less well to H1N1
and H5N1.
- Neutralizing activity of all four mAbs was demonstrated against
H1N1 and H3N2.
“Tuberculosis is one of the most common and deadly diseases in
the World. Up to one third of the World’s population has been
infected with the bacterium Mycobacterium tuberculosis but does not
have active disease,” said Gerald W. Fischer, MD, CEO of Longhorn
Vaccines and Diagnostics. “The heat shock protein may play a
significant role in shielding the bacterium from the immune system
and allowing it to survive. The data being presented suggests that
both our heat shock protein vaccine candidate and monoclonal
antibody cocktail could play a significant role in preventing and
treating multi-drug resistant tuberculosis infections.”
Mycobacterium tuberculosis (MTB) is a virus that is becoming
increasingly resistant to antibiotics and a key pathogen
contributing to antimicrobial resistance worldwide. The third
study, conducted by the University of Pretoria, explored Longhorn’s
monoclonal antibodies for the prevention and treatment of
infections caused by MTB and gram-positive bacteria. The study
analyzed the binding capabilities of IgG2a (anti- heat shock
protein (HSP16.3)) and IgG2b (anti- Peptidoglycan (PGN)) mAbs to
clinical MTB isolates. Results found:
- Both IgG2a and IgG2b mAbs demonstrated good binding activity to
live and ethanol-killed MTB, and to mid-logarithmic and stationary
phase MTB.
- The mAbs demonstrated good binding to live clinical MTB
isolates at concentrations as low as 0.25 µg/mL.
For more information about Longhorn, visit www.LHNVD.com.
About Longhorn Vaccines and Diagnostics
Longhorn Vaccines and Diagnostics is a closely held One Health
company based in Maryland that is developing broad coverage
vaccines and diagnostic tools for worldwide public health concerns
and to prevent future pandemics. Since its inception in 2006,
Longhorn has focused on developing broad coverage vaccines and
diagnostic tools that can impact a pandemic on a global scale and
at all socio-economic levels. Since pandemics flow between humans
and animals, Longhorn products play a significant role to surveil,
diagnose, prevent and treat the next infectious disease.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240427410246/en/
Longhorn Vaccines and Diagnostics
LLC Jeffrey Fischer Email: jeff@lhnvd.com Media Alexis Feinberg – ICR Westwicke PR Email:
alexis.feinberg@westwicke.com Investor
Relations Stephanie Carrington – ICR Westwicke IR Email:
stephanie.carrington@westwicke.com